Skip to content
Mazdutide / Studies
Synthetic analog · 34 amino acids · 4,563.1 Da

Mazdutide studies and research data

PepBank has 28 mazdutide studies with results. 23 of them gave mazdutide, with 186 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 186 results and 61 papers. Newer studies from Europe PMC

Results in people
161
87% of 186 results
Results in animals
16
9% of 186 results
Results in lab cells
9
5% of 186 results
From computer models
0
0% of 186 results
The molecule

Mazdutide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Mazdutide (IBI362, LY3305677) is a synthetic 34-residue oxyntomodulin analog with Aib at position 2, a C20 fatty diacid side chain on Lys20 and a C-terminal amide. It is an agonist at the GLP-1 receptor and the glucagon receptor. Innovent Biologics develops it in China under license from Eli Lilly; Innovent reports NMPA approval for chronic weight management (2025-06-27) and for glycemic control in type 2 diabetes (2025-09-19). Lilly has run phase 2 studies in the United States; it is not approved by FDA or EMA.

Kind
Synthetic analog · 34 residues
Identifiers
ChEMBLCHEMBL5095358 (opens in a new tab)UNIIMB76Z4IBZ5 (opens in a new tab)DrugBankDB19099 (opens in a new tab)CAS2259884-03-0KEGGD12225 (opens in a new tab)IUPHAR13924 (opens in a new tab)
Parent
Analog of Oxyntomodulin (human) · residues 53-89KEGG D12225 classes mazdutide as an oxyntomodulin analog (DG03355). Substitutions are computed for this record by an ungapped position-by-position comparison of KEGG D12225 with UniProt P01275 residues 53-89. Mazdutide has 34 residues; oxyntomodulin residues 35-37 (NIA) have no counterpart.
Development
Approved in China onlyInnovent Biologics (China, under license from Eli Lilly); Eli Lilly (outside China)Approved in China only. Phase 3 GLORY-1 (NEJM 2025, PMID 40421736). Outside China the highest phase found is phase 2 (Lilly, United States). ChEMBL max_phase is 3 and does not reflect the China approval. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
TargetActionEvidence
Glucagon-like peptide 1 receptorGLP1RP43220 (opens in a new tab)Agonistprimary literatureSource (opens in a new tab)
Glucagon receptorGCGRP47871 (opens in a new tab)Agonistprimary literatureSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

34 amino acids · 3 modifications

H-
Residues 1 to 10:
HQGTFTSDY
Residues 11 to 20:
SKYLDEKKA
Residues 21 to 30:
EFVEWLLEGG
Residues 31 to 34:
PSSG
  • HydrophobicA V I L M
  • AromaticF W Y
  • PositiveK R H
  • NegativeD E
  • PolarS T N Q
  • SpecialC G P
  • Non-canonicalX
  • Modified residue

Modifications

Aib2
Non-canonical residue
2-aminoisobutyric acid (2-methylalanine) at position 2. GSRS: amino acid substitution with 2-aminoisobutyric acid (UNII 1E7ZW41IQU).
Lys20
Lipidation
Lys20 N6 is acylated with a linker of two [2-(2-aminoethoxy)ethoxy]acetyl (OEG) units, then L-gamma-Glu, then icosanedioyl (19-carboxynonadecanoyl, C20 diacid). GSRS substituent: N6-(N-(hydrogen icosanedioyl)-gamma-Glu-bis(iminobis(ethylenoxy)acetyl))-lysine (UNII NVV1P9GCY2).
Gly34-NH2
C-terminal amide
C-terminal glycinamide (GSRS).

Alignment to Oxyntomodulin (human)

Calculated from the two sequences. Curated notes are shown as given.

19 of 34 aligned residues identical (56%) · 14 substitutions · 1 non-canonical residue · Oxyntomodulin (human) 1–34

  • Top row: Oxyntomodulin (human) (parent)
  • Bottom row: Mazdutide
HQGTFTSDY
SKYLDA
FVWL
  • Same as parent
  • Substituted
  • Non-canonical or D-form
  • Added
  • Gap
  • Modified side chain or end
  • Parent context

Differences from the parent

  1. 1Parent 2 · analog 2Ser → Aib · Non-canonical residue2-aminoisobutyric acid (2-methylalanine) at position 2. GSRS: amino acid substitution with 2-aminoisobutyric acid (UNII 1E7ZW41IQU).
  2. 2Parent 16 · analog 16Ser → Glu · Substitution
  3. 3Parent 17 · analog 17Arg → Lys · Substitution
  4. 4Parent 18 · analog 18Arg → Lys · Substitution
  5. 5Parent 20 · analog 20Gln → Lys · SubstitutionLys20 carries the lipid side chain. Lys20 N6 is acylated with a linker of two [2-(2-aminoethoxy)ethoxy]acetyl (OEG) units, then L-gamma-Glu, then icosanedioyl (19-carboxynonadecanoyl, C20 diacid). GSRS substituent: N6-(N-(hydrogen icosanedioyl)-gamma-Glu-bis(iminobis(ethylenoxy)acetyl))-lysine (UNII NVV1P9GCY2).
  6. 6Parent 21 · analog 21Asp → Glu · Substitution
  7. 7Parent 24 · analog 24Gln → Glu · Substitution
  8. 8Parent 27 · analog 27Met → Leu · Substitution
  9. 9Parent 28 · analog 28Asn → Glu · Substitution
  10. 10Parent 29 · analog 29Thr → Gly · Substitution
  11. 11Parent 30 · analog 30Lys → Gly · Substitution
  12. 12Parent 31 · analog 31Arg → Pro · Substitution
  13. 13Parent 32 · analog 32Asn → Ser · Substitution
  14. 14Parent 33 · analog 33Arg → Ser · Substitution
  15. 15Parent 34 · analog 34Asn → Gly · SubstitutionGly34 is C-terminally amidated. C-terminal glycinamide (GSRS).

Basis: KEGG D12225 classes mazdutide as an oxyntomodulin analog (DG03355). Substitutions are computed for this record by an ungapped position-by-position comparison of KEGG D12225 with UniProt P01275 residues 53-89. Mazdutide has 34 residues; oxyntomodulin residues 35-37 (NIA) have no counterpart.

Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.

Properties

From identity sources

Formula
C210H322N46O67
Molecular weight
4,563.07 g/mol
Monoisotopic mass
4,560.3203 Da

Calculated from the sequence

Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Average mass
Not calculated
Monoisotopic mass
Not calculated
Isoelectric point (pI)
Not calculated
Net charge at pH 7.4
Not calculated
GRAVY (hydropathy)
Not calculated
Extinction coefficient, 280 nm (Cys reduced)
8,480 M⁻¹ cm⁻¹
5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index
Not calculated
Aliphatic index
Not calculated
Boman index
Not calculated
Hydrophobic moment (μH)
Not calculated
  • 1 non-canonical residue (X) is not included in calculated values.
  • Not included: lipid chain. Mass, charge and pI are not calculated; use the identity-source values.
  • Defined and validated for proteins; use with care for short peptides.
  • Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Composition

  • Hydrophobic15% (5)
  • Aromatic15% (5)
  • Positive15% (5)
  • Negative18% (6)
  • Polar21% (7)
  • Special15% (5)
  • Non-canonical3% (1)

34 residues. Each residue counts in one class; F and W count as aromatic.

A Ala1 · 3%
I Ile0 · 0%
L Leu3 · 9%
M Met0 · 0%
V Val1 · 3%
F Phe2 · 6%
W Trp1 · 3%
Y Tyr2 · 6%
H His1 · 3%
K Lys4 · 12%
R Arg0 · 0%
D Asp2 · 6%
E Glu4 · 12%
N Asn0 · 0%
Q Gln1 · 3%
S Ser4 · 12%
T Thr2 · 6%
C Cys0 · 0%
G Gly4 · 12%
P Pro1 · 3%
X Xaa1 · 3%

3D structure

PredictedAlphaFold DB · P01275

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

  • Very high (pLDDT > 90)
  • Confident (90 > pLDDT > 70)
  • Low (70 > pLDDT > 50)
  • Very low (pLDDT < 50)

Predicted model of the whole UniProt entry P01275, not an experimental structure of Mazdutide. Mazdutide = residues 53–89.

AlphaFold DB, EMBL-EBI and Google DeepMind · CC BY 4.0

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

Helical wheel of Mazdutide, 34 residues at 100 degrees per residue. Hydrophobic moment 0.11 pointing at 332 degrees.His 1, Eisenberg consensus (normalized) -0.40H1Non-canonical 2X2Gln 3, Eisenberg consensus (normalized) -0.85Q3Gly 4, Eisenberg consensus (normalized) 0.48G4Thr 5, Eisenberg consensus (normalized) -0.05T5Phe 6, Eisenberg consensus (normalized) 1.19F6Thr 7, Eisenberg consensus (normalized) -0.05T7Ser 8, Eisenberg consensus (normalized) -0.18S8Asp 9, Eisenberg consensus (normalized) -0.90D−9Tyr 10, Eisenberg consensus (normalized) 0.26Y10Ser 11, Eisenberg consensus (normalized) -0.18S11Lys 12, Eisenberg consensus (normalized) -1.50K+12Tyr 13, Eisenberg consensus (normalized) 0.26Y13Leu 14, Eisenberg consensus (normalized) 1.06L14Asp 15, Eisenberg consensus (normalized) -0.90D−15Glu 16, Eisenberg consensus (normalized) -0.74E−16Lys 17, Eisenberg consensus (normalized) -1.50K+17Lys 18, Eisenberg consensus (normalized) -1.50K+18Ala 19, Eisenberg consensus (normalized) 0.62A19Lys 20, Eisenberg consensus (normalized) -1.50K+20Glu 21, Eisenberg consensus (normalized) -0.74E−21Phe 22, Eisenberg consensus (normalized) 1.19F22Val 23, Eisenberg consensus (normalized) 1.08V23Glu 24, Eisenberg consensus (normalized) -0.74E−24Trp 25, Eisenberg consensus (normalized) 0.81W25Leu 26, Eisenberg consensus (normalized) 1.06L26Leu 27, Eisenberg consensus (normalized) 1.06L27Glu 28, Eisenberg consensus (normalized) -0.74E−28Gly 29, Eisenberg consensus (normalized) 0.48G29Gly 30, Eisenberg consensus (normalized) 0.48G30Pro 31, Eisenberg consensus (normalized) 0.12P31Ser 32, Eisenberg consensus (normalized) -0.18S32Ser 33, Eisenberg consensus (normalized) -0.18S33Gly 34, Eisenberg consensus (normalized) 0.48G34
μH, residues shown
0.108
μH, best 11-residue window
—
Arrow direction
332°
Residues
34 · 2 rings of 18 · 1 X not scored
HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table
PositionResidueAngleEisenberg consensus (normalized)
1H0°-0.40
2X100°not scored
3Q200°-0.85
4G300°0.48
5T40°-0.05
6F140°1.19
7T240°-0.05
8S340°-0.18
9D80°-0.90
10Y180°0.26
11S280°-0.18
12K20°-1.50
13Y120°0.26
14L220°1.06
15D320°-0.90
16E60°-0.74
17K160°-1.50
18K260°-1.50
19A0°0.62
20K100°-1.50
21E200°-0.74
22F300°1.19
23V40°1.08
24E140°-0.74
25W240°0.81
26L340°1.06
27L80°1.06
28E180°-0.74
29G280°0.48
30G20°0.48
31P120°0.12
32S220°-0.18
33S320°-0.18
34G60°0.48
Results by area

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Trials and papers
Status and safety
Data

Compare